Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Additional a.i. generated information for those investors interested in KBLB
Kraig Biocraft Laboratories (Kraig Labs) uses genetically engineered silkworms to produce spider silk, a highly durable and flexible protein. Beyond spider silk, Kraig Labs’ technology potentially allows for the production of other large, complex proteins that have applications in medicine, industry, and biotechnology. Here are some examples of large proteins that Kraig Labs' silkworms could theoretically produce:
1. Antibodies
Antibodies are large Y-shaped proteins used by the immune system to neutralize pathogens. They have applications in diagnostics, therapeutics, and research. Kraig Labs could potentially engineer silkworms to produce monoclonal antibodies, which are widely used in cancer treatments and autoimmune disease therapies.
2. Collagen
Collagen is the most abundant protein in mammals and is a primary component of connective tissues like skin, tendons, and bones. Synthetic production of collagen is useful in cosmetics, wound healing, and tissue engineering. Silkworms could be genetically modified to produce recombinant collagen with specific properties tailored to medical or cosmetic applications.
3. Enzymes
Enzymes are proteins that catalyze biochemical reactions and are widely used in industries such as pharmaceuticals, food and beverage, and biofuels. Large enzymes like cellulases, amylases, or proteases could be produced using silkworms, potentially offering a cost-effective and scalable method for enzyme production.
4. Growth Factors
Growth factors are proteins that regulate cell growth and division. They are used in regenerative medicine and tissue engineering. Examples include epidermal growth factor (EGF) and fibroblast growth factor (FGF). Producing these proteins in silkworms could help meet the growing demand for these therapeutic proteins in medical treatments.
5. Structural Proteins
In addition to spider silk, other structural proteins like elastin (which provides elasticity to tissues) or keratin (found in hair and nails) could be produced using silkworms. These proteins have applications in cosmetics, medical materials, and textiles.
6. Vaccines and Viral Proteins
Large proteins used in vaccine production, such as viral proteins for subunit vaccines, could also be synthesized. Kraig Labs could use its platform to produce vaccine components or adjuvants more efficiently.
7. Hormones and Receptors
Proteins like insulin (used for diabetes treatment) and erythropoietin (used to treat anemia) are other examples of large proteins that could be produced. Receptor proteins like cytokine receptors could also be synthesized for research and therapeutic purposes.
Potential Advantages
The use of silkworms as biofactories could potentially offer advantages over traditional production methods in bacteria, yeast, or mammalian cells by combining high yield, reduced costs, and simplified purification processes.
2nd QTR 10-Q next week
A paragraph from the April 8th PR:
“We have been following developments at Kraig Labs for many years and are very happy now to be working directly with them,” said Dr. Le Quang Tu, President of the Vietnamese Sericulture Association. “We believe that Kraig’s technology will have a significant positive impact on our industry. They have applied a thoughtful, step-by-step approach. Now, we will take a step together.”
KBL has not deviated from their step by step approach, releasing developments weekly. Seems exactly what interested the VSA to sign an agreement.
For all of us long term investors the past 96 hours have been an interesting opportunity.
Even more than a predicted pullback by some to acquire additional shares, SickZones
recent released photo of men and women leaders of one of a country's leading
industries, standing together smiling and toasting a relationship, leads me to believe my
long term investment into this OTC company has a promising future.
Kraig Labs’ new Vietnam facility to boost spider silk production
In the December 2023 issue of Nature Biotechnology: Bioengineered Spider Silk Without Critters
Several companies were named along with KBL. The usual Bolt, Amsilk, etc.
Each company had partnerships listed. KBL partners: (1) Kings, (2) U.S. Army, (3) Warwick Mills
Reading today's PR: KBL (CEO) has control over the end product.??
1. KBL produces DS
2. KBL sells DS to the JV Partnership (King + KBL)
3. JV Partnership sells branded Spydasilk to industry: Read June 22, 2022 PR
WebSlinger-- Good morning.
KBL does indeed have a valuable innovative fiber platform. I don't know of too many companies that have created Monster Silk, Dragon Silk or NPSS. Although no revenues, this does not equate to worthless innovation. There are countless examples of big pharma purchasing a biotech company with a very innovative drug development platform, for billions, yet years away from eventual FDA approval for drug #1.
We all want production numbers but I am as interested in KBL's pending/published patent applications receiving granted status adding protection to the innovation.
Webslinger
KBL is in the process of active negotiations with public and private sector actors. Your opinion, two each.
"New friends:" (1). India is providing sericulture expertise. (2). India-- tremendous producer of raw silk. (3) India lacking in textile innovation. (4). Do you think India realizes KBL's fiber(s) innovation? (5). In there a more comprehensive relationship on the table?
Webslinger---
I need your opinion before I invest further dollars into KBL.
* We already know Vietnam is one of the largest raw silk exporting countries to India.
* We also know India's demand for silk outweighs its production and the gap seems to be increasing.
* We know the best of the best sericulture experts from India have already provided expertise to Kraig's US operations and in Q1 to Prodigy & other KBL affiliates.
* We know after a stellar UND career Dr. Fraser gave a positive description of KBL. I do not think he would risk his reputation on a scumbag run corporation.
* We know for the past 36 + months KBL has been consistent and timely with their SEC reporting. I appreciate this with an OTC.
Question: Do you believe Vietnam and India will expand their Raw Silk, mulberry, export-import relationship and will this relationship involve KBL's new genetically engineered silk's? And will the current operational expertise provided by India's experts be expanded to include some manner of a financial collaboration?
Interesting to see KBL remains a listed company within the two tabs (1) Eco-engineering and (2) Product development as a
company asset of the brand, Polartec on the Milliken.com website. It's been approximately 1,695 days since the infamous
April 17, 2019 PR. No additional KBL-Polartec news since that PR that I am aware of and more than enough time to have
scrubed the website of names since the Milliken purchase of Polartec.
An oversight, maybe.
Q3 10-Q Next Week? Most likely
Merger of "significant elements", including scientific personnel, from the UND Fraser Laboratory..... besides the addition of scientists, what elements of significance are included in the merging process.
MEDICAL BREAKTHROUGHS
nerve scaffolding
protein construction
I want to thank the two posters who submitted the AFRL article published today, mentioning Musk Ox and Keratin. The article prompted me to review two of Kraig's pending patents.
Synthesis of High Molecular Weight Proteins Using Inteins.
Synthesis of Non-Native Proteins in Bombyx Mori By Modifying Sericin Expression.
Within several embodiments and claims one will find the following words.
* Keratin
* Human Keratin
* Fibrous Keratin
I am hoping for all of us the company receives GRANTED STATUS on many of the claims.
An updated "published date" for the filed patent:
"Synthesis of High Molecular Weight Proteins Using Inteins"
Previous date: 1-20-22
New date: 4-26-23
Perhaps expanded European coverage? Significant? Too busy to compare the documents.
In two weeks it will be one year since two pending patent applications were published. The world has now had access to view the claims of each for a year. My hope is "soon" we will be provided an update as to the status of each listed claim.
Many may want spider silk ties, hoodies, sneakers, etc but the creation of a novel production platform for complex proteins should and will be noticed by Big Pharma and enthusiastically applauded by the majority of shareholders.
Drug Development is costly, very time consuming and takes many skilled individuals just to begin the process. A 2nd hope for 2023 is for KBL to structure relationships with Big Pharma(s) outlining pathway(s) to bring various complex proteins, using this novel method of production, to the laboratory for initial scientific study.
The technology to produce elastin, keratin and human collagen is groundbreaking exciting. The possibilities of producing "and many others at comparatively very low prices" is *********** exciting.
Could many others include?
Human Insulin
Human Growth Hormone
Clotting Factors
Monoclonal Antibodies
Erythropoietin
Numerous world wide pharmas involved with the production of these protein structures.
Not sure if this patent application (August 12, 2021 Publication)is old information or not but I found the PDF an interesting read.
1. Search Google Patents
2. US 20210246471A1
3. Download PDF
Interesting connection with one of the inventors to Utah State University.
There are numerous sections supporting management's comments from the BBC interview. Some include.
0008
0015
0070
0071
0072
Interesting that one of the chosen potential directors, Julie Bishop, (Verizon Executive) remains listed as a Director under the executive section of KBLB on the Charles Schwab trading platform. She has been listed on the site soon after announced by KT.
I would expect any accomplished individual once chosen to become a director that subsequently felt the OTC company had a failed future or suspected the CEO was benefiting himself at the expense of shareholders would immediately contact the company or Charles Schwab and have their named removed from any association.
My apology if this news has already been posted. Just viewed TK's LinkedIN. He is a current member of Kraig Biocraft Labs:
Scientific Advisory Board
April 2018 to Present
Good to see Kraig listed among many retailers and raw material suppliers in the "Sourcing Journal" > News > page 13
While KBL responds to fill the backlog of material requests let's hope some of the spider silk fibers that arrived from Prodigy will somehow navigate themselves into DuPont Laboratories.
Today, an "Innovations in Textiles" article announced the acquisition of Core Matrix Technology from Tex Tech Inc.
DuPont states: "With the combination of Core Matrix Technology and our current and future fiber technologies we are well positioned to offer the best, most flexible and lightest weight solutions available."
FUTURE FIBER TECHNOLOGIES?
Submitted by KBL
It's possible the panels developed exceeded the performance criteria originally outlined by the Army and that the subsequent fiber(s) requested were quickly transferred into "stealth mode". Major military projects that advance performance and create advantage are not readily or publicly talked about.
Offering/uplist, not sure. For merging companies, very possible for the patent silence.
Mr. KT
Today, tomorrow or sometime this week would be a great time for a filler PR (before expected production PR's)regarding the status of the once filed provisional patents in May 2019.
In your last PR you stated significant progress occurred related to genetics and R&D.
Prior to the expiration date of the provisional filing, were actual patent (non-provisional)applications filed?
You are correct Web.
But prior to the 12 month expiration period were applications (non-provisional)filed through Workman Nydegger for the science/technologies.
We should know. There was sufficient time to adjust, delete or add claims.
May 22, 2019 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announces today that it has submitted five new provisional patent applications, for technologies related to its recombinant spider silk technologies. These applications cover a broad range of technologies in the creation, screening, and production of new recombinant proteins. These new applications expand beyond the Company’s publicly disclosed silkworm and silk technologies, to include advanced construction systems, methods, and non-native proteins.
In November, of 2018, the Company retained Workman Nydegger as its Intellectual Property counsel and expects to utilize their expertise in prosecuting these, and all future, patent applications.
“Our R&D team is constantly looking for opportunities to strengthen our competitive potions, products, and processes. The recently submitted provisional patent applications cover key technologies and processes, invented by Dr. Kane and our team, as well as new applications that build upon our technologies,” said Kraig’s COO Jon Rice. “These new technologies have the potential to significantly reduce future R&D costs and break open new markets for recombinant protein products, reaching far beyond silks and apparel.”
It has been 17 months since the release of this PR. Have the provisional patent applications been updated to a non-provisional filing status?
I believe during a "Quiet Period" there is some information that could be released.
A title is not listed adjacent to her name.
However, on two brokerage websites (TD & Schwab)the name Julie Bishop has been listed as Director for at least 6 months.
A couple of months ago JNJ announced the purchase of the biotech company (Momenta). For 6.5B. I do not believe Momenta yet has an FDA approved product but a unique pipeline of therapeutics and biosimilars. I think the purchase review concludes September 30th.
KBLB could become an R&D fiber polymer production subsidiary for many companies, certainly, Dupont, JNJ, DOW and Milliken. Each has future high performance polymer blockbuster product hope.
But as many esteemed posters have stated KBLB needs to show them (anyone) more science (patents), structure, compliance and production.
GLTA
My favorite line in the 10-Q is on page 26, 5th line.
Spider silk-based biomaterials: fostering innovation in countless industries: June 15, 2020
This article in Innovation News Network has probably been read by the masses already but is a first read for me. What a future opportunity for KBL. KBL is not mentioned but if KT has indeed created 97% pure spider silk along with the ability to tailor the fiber towards a specific application (as requested by the Army)then KT- Kraig has an incredible future.
By the way, provisional patents were filed over 12 months ago. Should we not be receiving news that these documents were moved to a "non-provisional" filing status?
Let's hope so and if granted one day the value of KBL should increase substantially.
For months, after he confirmed his acceptance in an April 6th PR, it didn't appear CEO Thompson was listed as a speaker for the 2020 SynBio Market Conference scheduled for November 3rd.
Today, he was listed as a speaker with bio and photo.
This SynBio Forum may allow for additional scientific information to be released after some hopeful eye opening PR's over the next several weeks.
Exactly. My reason for writing the post.
The potential of the science is incredible and then to take the time to test, observe, document and then write your scientific ideas to then be discussed and refined by Workman Nydegger is time consuming and expensive.
Then no follow-up, followed by expiration.
At this time I will remain positive not believing this could occur.
From some experience it seems we should be approaching the time for some comments,approvals, rejections from the patent office.
It's been over 14 months since the announcement of the filing of 5 provisional patent applications.
Creation, screening and production of new recombinant proteins should be of interest to at least several S&P 500 companies.
Would have liked at least a "we remain positive" update from Kraig via Workman Nydegger.
Perhaps should have occurred before the beginning of the QP.
Yes,cool stuff.
Wonder if there is any connection with the following.
Crew Dragon
Dragon Capsule
Dragon Silk
Astronaut Gloves: From the capsule systems are activated via "touch Screen" display. Interesting that Dragon Silk transfers heat better than most metals in addition to being extremely strong and flexible.
An interesting read that may have been posted already. Hopefully, a future application for Kraig's engineered spider silk based polymers.
"Wild Silkworms Produce Proteins Primed For Bioprinting"
Scientific American December 1, 2019
Material science labs working with Dr. Kane may have produced a major scientific breakthrough, a product that crosses into many industries.
Combining segments of the incredibly strong natural polymer such as Nacre with a Kraig designed spider silk based polymer would propel KBL into discussions with many DOW 50 companies.
I believe we are in for some very good news, possibly KBL dividing into two business segments.
1. KBL hybrid silks utilizing the Prodigy-Vietnam subsidiary and the silk worm engine. Monster Silk, Dragon Silk and additional new silks tailored for the many existing and future markets.
Nike
Adidas
MFFF-A
Levi Straus
UA
New Balance
Polartec-Milliken
2. Synthetic Spider Silk Based Polymers. KBL's molecular biology lab has isolated the gene sequencing of materials created by various exotic species; the very sequences that allow these materials to have incredible strength, flexibility/stiffness, and weighing next to nothing. Combining these newly discovered sequences with the proprietary sequencing of KBL's specific hybrid silks MAY create fibers with unlimited potential for industry.
DuPont: A new fiber to replace Kevlar. We have known any genetic engineered silk, by itself, would probably not prevent bullet penetration. Bob, this could be your answer for DuPont.
Dow Chemical: New biodegradable fibers with strength to replace many plastics. Interesting to find Dow Corporate is only 112 miles from Ann Arbor, MI.
JNJ: Invasive or otherwise medical devices.
Regardless of the endless possibilities, Kim needs to outline some licensing agreement, partnership or other type of revenue stream.
If he delays announcing some form of business venture (in the current news climate)then I believe the April 16th webcast may have the same impact as announcing a Major Scientific Breakthrough on.
November 22, 1963 or July 20, 1969.
I am very hopeful for all fellow KBL investors.
I also agree. I am looking at the delay from another viewpoint.
Announcing a MAJOR SCIENTIFIC BREAKTHROUGH" by an OTC company to compete with a worldwide pandemic would be ill advised.
I do not believe the announcement will involve a new fiber, greater than DS 2.0 or any other. I still hold onto the idea that a new polymer or sequence of monomers was developed that would change the characteristics of a material used throughout the planet.
The Feb. 27th PR stated: Major Scientific Breakthrough in Spider Silk Based Polymers, NOT Spider Silk Based Fibers.
Is it possible the decision today was a joint decision. A decision by Kim Thompson and management from another company that would also be a participant during the webcast?
On April 17, 2019 KBL's collaboration with Polartec was announced. Soon thereafter Polartec was acquired by Milliken & Company. The possible connection of KBL and Milliken is real.
Interesting, the revised date of April 16, 2020 is exactly one year from the Polartec collaboration announcement. Furthermore, researching the history of Milliken, I cannot find a more socially responsible PRIVATE corporation in the U.S. Their material science/products are unique and their history of acquiring assets is impressive. And, as important, they have a remarkable history of doing the "Right thing, Right."
Delaying the webcast announcing a major scientific breakthrough, a breakthrough that may have nothing to do with the immediate saving of lives, may indeed be the socially responsible thing to do.